Article

Akorn gains stake in Aciex

Akorn has acquired a minority stake in Aciex Therapeutics, a Westborough, MA-based pharmaceutical company focused on developing first-in-class products to treat ocular diseases. Akorn is a niche pharmaceutical company engaged in the development, manufacture, and marketing of multisource and branded pharmaceuticals. The terms of the deal and the size of the stake were not disclosed.

Lake Forest, IL-Akorn has acquired a minority stake in Aciex Therapeutics, a Westborough, MA-based pharmaceutical company focused on developing first-in-class products to treat ocular diseases. Akorn is a niche pharmaceutical company engaged in the development, manufacture, and marketing of multisource and branded pharmaceuticals. The terms of the deal and the size of the stake were not disclosed.

Aciex’s product pipeline includes both clinical stage and pre-investigational new drug assets. The acquisition was accompanied by a global licensing deal that gives Akorn rights to a novel over-the-counter eye-care product, and a manufacturing agreement for one of Aciex’s lead prescription candidates.

“We are excited to partner with Aciex and have the opportunity to bring novel over-the-counter and prescription eye-care products to the market,” said Raj Rai, Akorn’s chief executive officer. “With this partnership, we have rounded out our strategy in ophthalmology to include generics, branded, and over-the-counter pharmaceuticals.” 

Akorn’s ophthalmology business markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes. Akorn also offers custom research and development and manufacturing services for injectable and ophthalmic products.

In May, Akorn acquired Advanced Vision Research, a firm that specializes in the over-the-counter dry eye market.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.